Stryker Bribery Probes Closed by U.S. Justice Dept. and SEC

Stryker, the medical technology company, announced that the U.S. Justice Department and the Securities and Exchange Commission have concluded their investigations into potential anti-bribery law violations. These probes, which commenced in May 2023, focused on business activities in an undisclosed foreign country to determine compliance with the Foreign Corrupt Practices Act (FCPA). The closure of these federal inquiries removes a significant regulatory overhang for Stryker, positively impacting investor sentiment. The company further stated that ongoing inquiries by certain foreign authorities are not expected to materially affect its financial statements. This development is generally seen as bullish for Stryker's stock (SYK) as it alleviates uncertainty surrounding potential legal liabilities.